Mark Slevin, PhD, FAHA, FIBMS, FRCPath (Angiogenesis Research)
School of Healthcare Science, Manchester Metropolitan University, UK
Prof. Slevin is Chair in Cell Pathology in the School of Healthcare Science, Manchester Metropolitan University. He has full Professorial titles at the Universities of Targu Mures (Romania) and Griffith University, Brisbane (Australia). He is also visiting Chair in Clinical Biomedicine at the ICCC-CSIC, St Pau Hospital Barcelona and Adjunct Professor at both Almajmaah and Ha’il Universities in Saudi Arabia. Prof. Slevin is also a Fellow of the Royal College of Pathologists and has been since 2008. For work completed during a sabbatical period as Chair in clinical Biomedicine at St Pau Hospital, Prof Slevin was awarded the title of “Eminent Scientist of the year in Cardio-Pathology” by the International Research promotions Council 2011 and is currently the European representative for this committee. He is also a nominated Faculty Row ‘Super Professor’.
Prof. Slevin is Editor-in Chief of the Journal Vascular Cell and Senior Associate editor of Brain Pathology and Nature’s Scientific Reports amongst others. He is a nominated Fellow of American Heart and Stroke Association and of the Institute of Biomedical Scientists in the UK.
Prof. Slevin is a recognized expert in the field of angiogenesis research and in particular in investigations of the role of angiogenesis in both stroke and cardiovascular disease. He was the first to identify the potent anti-angiogenic properties of opticin in association with proliferative diabetic retinopathy, signalling mechanism of hyaluronan, and the importance of monomeric C-reactive protein in brain pathology.Prof. Slevin, has worked with and managed numerous senior post-doctoral research scientists,throughout the last decade, obtaining support from numerous external organizations including the Wellcome Trust, Diabetes UK, the Royal Society, The Pathological Society of Great Britain and Northern Ireland.